Daria Lemann-Blumenthal Takes Leadership at NanoDrops
Lemann-Blumenthal, a seasoned business leader in the ophthalmic technology sector, has been appointed as the new CEO of NanoDrops. Previously, she led BELKIN Vision to a successful acquisition by Alcon, a global leader in eye care innovations.
Experience and Vision for Growth
NanoDrops, known for its cutting-edge vision correction technology, focuses on developing innovative solutions to enhance visual performance. By blending laser technology with nanoparticles, the company aims to provide effective treatments for presbyopia and myopia. As a co-founder and former CEO of BELKIN Vision, Lemann-Blumenthal played a vital role in creating the Direct Selective Laser Trabeculoplasty (DSLT), making glaucoma treatment more accessible.
Strategic Leadership
With her extensive experience of over two decades in ophthalmology, Lemann-Blumenthal holds an LL.B. and an executive MBA. In her role at NanoDrops, she is set to collaborate closely with co-founder and Chief Medical Officer Prof. David Smadja, MD, whose profound medical knowledge and experience lead the company’s clinical endeavors.
Expertise that Drives Innovation
Prof. David Smadja, who chairs the Innovation Committee of the International Society of Refractive Surgery and serves as an associate professor of ophthalmology, recognizes the importance of Lemann-Blumenthal's business acumen. He remarked, "Daria has precisely the experience we need to direct NanoDrops in its growth phase, especially as we approach human clinical trials."
Enhancing Patient Care
Assaf Barnea, Chairman of the Board and Managing Partner of Sanara Capital, emphasized the significance of Lemann-Blumenthal’s background in fostering the company’s future. He stated, "Daria's proven track record in business development will undoubtedly propel NanoDrops toward becoming a model of bio-convergence in patient care."
A Bright Future Ahead
Associate Professor Arthur Cummings, MD, Chairman of the Medical Advisory Board at NanoDrops, expressed enthusiasm about Lemann-Blumenthal’s appointment. He noted her remarkable leadership and ability to orchestrate strategic growth as evidenced by her success at BELKIN Vision. Cummings believes that her appointment heralds an exciting new chapter for the company.
About NanoDrops
Founded in 2020, NanoDrops is dedicated to creating individualized vision correction solutions through a unique corneal imprint procedure that utilizes nanoparticle technology. This novel method not only ensures a minimally invasive approach but also allows patients to adjust their vision according to their evolving needs.
Frequently Asked Questions
What is the role of Daria Lemann-Blumenthal at NanoDrops?
Daria Lemann-Blumenthal has been appointed as the CEO of NanoDrops, focusing on advancing the company's innovative vision correction solutions.
What is the background of Daria Lemann-Blumenthal?
She is a seasoned business leader in the ophthalmic technology sector and was formerly the CEO of BELKIN Vision, leading the company to a notable acquisition.
What technology is NanoDrops developing?
NanoDrops is developing minimally-invasive vision correction technology that integrates laser solutions with nanoparticles for presbyopia and myopia treatments.
When was NanoDrops founded?
NanoDrops was established in 2020 and has focused on innovative solutions in the eye care industry since its inception.
Who is David Smadja?
Prof. David Smadja, MD, is the co-founder and Chief Medical Officer of NanoDrops, contributing his medical expertise to the company's strategic growth.
